Top

Published in:

01-12-2013 | PRECLINICAL STUDIES

Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme

Authors: Elita F. da Silveira, Janaine M. Chassot, Fernanda C. Teixeira, Juliana H. Azambuja, Gabriela Debom, Fátima T. Beira, Francisco A. B. Del Pino, Adriana Lourenço, Ana P. Horn, Letícia Cruz, Roselia M. Spanevello, Elizandra Braganhol

Published in: Investigational New Drugs | Issue 6/2013

Summary

Glioblastoma multiforme (GBM) is the worst and most common brain tumor, characterized by high proliferation and invasion rates. Nanoparticles of biodegradable polymers for anticancer drug delivery have attracted interest in recent years since they provide targeted delivery and may overcame the obstacle imposed by blood–brain barrier. Here we investigated the antitumoral effect of ketoprofen-loaded nanocapsules (Keto-NC) treatment on in vitro and in vivo glioma progression. We observed that Keto-NC treatment decreased selectively the cell viability of a panel of glioma cell lines, while did not exhibited toxicity to astrocytes. We further demonstrate that the treatment with sub-therapeutic dose of Keto-NC reduced the in vivo glioma growth as well as reduced the malignity characteristics of implanted tumors. Keto-NC treatment improved the weight, the locomotion/exploration behavior of glioma-bearing rats. Importantly, Keto-NC treatment neither induced mortality or peripheral damage. Finally, Ketoprofen also altered the extracellular nucleotide metabolism of peripheral lymphocytes, suggesting that antiinflammatory effects of ketoprofen could also be associated with the modulation of the adenine nucleotide metabolism in lymphocytes. Data indicate at first time the potential of Keto-NC as a promising therapeutic alterative to GBM treatment.

Stupp R, Hegi ME, Gilbert MRA (2007) Chakravarti Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25:4127–4136CrossRefPubMed

Soffietti R, Leoncini B, Ruda R (2007) New developments in the treatment of malignant gliomas. Expert Rev Neurother 7:1313–1326CrossRefPubMed

Brigger I, Dubernet C, Couvreur P (2002) Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev 54:631–651CrossRefPubMed

Rahman M, Hoh B, Kohler N, Dunbar EM, Murad GJ (2012) The future of glioma treatment: stem cells, nanotechnology and personalized medicine. Future Oncol 8(9):1149–1156CrossRefPubMed

Chavany C, Saison-Behmoaras T, Le Doan T, Puisieux F, Couvreur P, Helene C (1994) Adsorption of oligonucleotides onto polysohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm Res 11:1370–1378CrossRefPubMed

Couvreur P, Tulkens P, Roland M, Trouet A, Speiser P (1977) Nanocapsules: a new type of lysosomotropic carrier. Fed Eur Biochem Soc Lett 84:323–326CrossRef

Bennis S, Chapey C, Couvreur P, Robert J (1994) Enhanced cytotoxicity of doxorrubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumour cells in culture. Eur J Cancer 1:89–93CrossRef

Colin de Verdiere AC, Dubernet C, Nemati F, Soma E, Appel M, Forte J (1997) Reversion of multidrug resistance with polyakylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer 76:198–205CrossRef

Huynh NT, Passirani C, Saulnier P, Benoit JP (2009) Lipid nanocapsules: a new platform for nanomedicine. Int J Pharm 379(2):201–209CrossRefPubMed

10.

Jain KK (2012) Nanobiotechnology-based strategies for crossing the blood–brain barrier. Nanomedicine 7(8):1225–1233CrossRefPubMed

11.

Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117(5):1175–1183PubMedCentralCrossRefPubMed

12.

Mantovani A (2009) Inflaming metastasis. Nature 457(7225):36–37CrossRefPubMed

13.

Watters JJ, Schartner JM, Badie B (2005) Microglial function in brain tumors. J Neurosci Res 81:447–455CrossRefPubMed

14.

Nietro-Sampedro M, Valle-Argos B, Gómez-Nicola D, Fernández-Mayoralas A, Nieto-Diaz M (2011) Inhibitors of glioma growth that reveal the tumour to the immune system. Med Insights 5:265–314

15.

Nogueira L, Ruiz-Ontañon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL (2011) The NFκB pathway: a therapeutic target in glioblastoma. Oncotarget 2(8):646–653PubMedCentralCrossRefPubMed

16.

Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5(4):297–309CrossRefPubMed

17.

Baud V, Kari M (2009) Is NF-kB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8:33–40PubMedCentralCrossRefPubMed

18.

Zanotto-Filho A, Braganhol E, Edelweiss MI, Behr GA, Zanin R, Schröder R, Simões-Pires A, Battastini AM, Moreira JC (2012) The curry spice curcumin selectively inhibits cancer cells growth in vitro and in preclinical model of glioblastoma. J Nutr Biochem 23(6):591–601CrossRefPubMed

19.

Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF (2011) Cyclooxigenase2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res 61(11):4375–4381

20.

Hussain M, Javeed A, Ashraf M, Al-Zaubai N, Stewart A, Mukhtar MM (2012) Non-steroidal anti-inflammatory drugs, tumour immunity and immunotherapy. Pharmacol Res 66(1):7–18CrossRefPubMed

21.

Schönthal AH (2010) Exploiting cyclooxygenase-(in)dependent properties of COX-2 inhibitors for malignant gliomatherapy. Anticancer Agents Med Chem 10(6):450–461CrossRefPubMed

22.

Bernardi A, Frozza RL, Hoppe JB, Salbego C, Pohlmann AR, Battastini AM, Guterres SS (2013) The antiproliferative effect of indomethacin-loaded lipid-core nanocapsules in glioma cells is mediated by cell cycle regulation, differentiation, and the inhibition of survival pathways. Int J Nanomed 8:711–729CrossRef

23.

Dovizio M, Bruno A, Tacconelli S, Patrignani P (2013) Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 191:39–65CrossRefPubMed

24.

Bernardi A, Braganhol E, Jäger E, Figueiró F, Edelweiss MI, Pohlmann AR, Guterres SS, Battastini AM (2009) Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett 281(1):53–63CrossRefPubMed

25.

Sanz-Motilva V, Martorell-Calatayud A, Nagore E (2012) Non-steroidal anti-inflammatory drugs and melanoma. Curr Pharm Des 18(26):3966–3978CrossRefPubMed

26.

Li W, Tang YX, Wan L, Cai JH, Zhang J (2013) Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts. Oncol Lett 3:923–928

27.

Kraus S, Naumov I, Arber N (2013) COX-2 active agents in the chemoprevention of colorectal cancer. Recent Results Cancer Res 191:95–103CrossRefPubMed

28.

Del Rosso A, Saldutto P, Di Pierro ED, Masciovecchio S, Galatioto GP, Vicentini C (2012) Impacts of antibiotic and anti-inflammatory therapy on serum prostate specific antigen in asymptomatic men: our experience. Urologia 79:37–40CrossRefPubMed

29.

Kamei S, Sakayama K, Tamashiro S, Aizawa J, Miyawaki J, Miyazaki T, Yamamoto H, Norimatsu Y, Masuno H (2009) Ketoprofen in topical formulation decreases the matrix metalloproteinase-2 expression and pulmonary metastatic incidence in nude mice with osteosarcoma. J Orthop Res 7:909–915CrossRef

30.

Da Frota Jr ML, Braganhol E, Canedo AD, Klamt F, Apel MA, Mothes B, Lerner C, Battastini AM, Henriques AT, Moreira JC (2009) Brazilian marine sponge Polymastia janeirensis induces apoptotic cell death in human U138MG glioma cell line, but not in a normal cell culture. Investig New Drugs 27(1):13–20CrossRef

31.

Takano T, Lin JH, Arcuino G, Gao K, Yang JM (2001) Nedergaard, Glutamato release promotes growth of malignant gliomas. Nat Med 7:1010–1015CrossRefPubMed

32.

Braganhol E, Morrone FB, Bernardi A, Huppes D, Meurer L, Edelweiss MI, Lenz G, Wink MR, Robson SC, Battastini AM (2009) Selective NTPDase2 expression modulates in vivo rat glioma growth. Cancer Sci 100(8):1434–1442CrossRefPubMed

33.

Böyum A (1968) Isolation of mononuclear cells and granulocytes from human blood, Isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Investig Suppl 97:77–89

34.

Leal DBR, Streher CA, Neu TN, Bittencourt FP, Leal CAM, Silva JEP, Morsch VM, Scheringer MRC (2005) Characterization of NTPDase (NTPDase 1: ecto-apyrase; ecto-diphosphohydrolase; CD39; E.C. 3.6.1.5) activity in human lymphocytes. BBA 1721:9–11PubMed

35.

Chan K, Delfert D, Junger KD (1986) A direct colorimetric assay for Ca²⁺ - ATPase activity. Anal Biochem 157:375–378CrossRefPubMed

36.

Bradford M (1976) A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein – dye binding. Anal Biochem 72:248–254CrossRefPubMed

37.

Giusti G, Gakis C (1971) Temperature conversion factors, activation energy, relative substrate specificity and optimum pH of adenosine deaminase from human serum and tissues. Enzyme 12:417–425PubMed

38.

Schaffazick SR, Freitas LL, Pohlmann AR, Guterres SS (2003) Caracterização e estabilidade físico-química de sistemas poliméricos nanoparticulados para administração de fármacos. Quím Nova 25:726–737CrossRef

39.

Mora-Huertas CE, Fessi H, Elaissari A (2010) Polymer-based nanocapsules for drug delivery. Int J Pharm 385:113–142CrossRefPubMed

40.

Cruz L, Soares LU, Dalla Costa T, Mezzalira G, Silveira N, Guterres SS, Pohlmann AR (2006) Diffusion and mathematical modeling of release profiles from nanocarriers. Int J Pharm 313:198–205CrossRefPubMed

41.

Quintanar-Guerrero D, Allémann E, Fessi H, Doelker E (1998) Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 24:1113–1128CrossRefPubMed

42.

Taphoorn MJ, Klein M (2004) Cognitive deficits in adult patients with brain tumours. Lancet Neurol 3:159–168CrossRefPubMed

43.

Wang YY, Liu SC, Yang Z, Zhang T (2011) Impaired hippocampal synaptic plasticity in C6 glioma-bearing rats. J Neurooncol 103(3):469–477CrossRefPubMed

44.

Eltzschig HK, Sitkovsky MV, Robson SC (2012) Purinergic signaling during inflammation. N Engl J Med 367(24):2322–2333PubMedCentralCrossRefPubMed

45.

Aktas Y, Andrieux K, Alonso MJ, Calvo P, Gürsoy RN, Couvreur P, Capan Y (2005) Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. Int J Pharm 298:378–383CrossRefPubMed

46.

Lee HC, Park IC, Park MJ, An S, Woo SH, Jin HO, Chung HY, Lee SJ, Gwak HS, Hong YJ, Yoo DH, Rhee CH, Hong SI (2005) Sulindac and its metabolites inhibit invasion of glioblastoma cells via down-regulation of Akt/PKB and MMP-2. J Cell Biochem 94(3):597–610CrossRefPubMed

47.

Lamprecht A, Benoit JP (2006) Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release 112:208–213CrossRefPubMed

48.

Zhang L, Zhang WP, Hu H, Wang ML, Sheng WW, Yao HT, Ding W, Chen Z, Wei EQ (2006) Expression patterns of 5-lipoxygenase in human brain with traumatic injury and astrocytoma. Neuropathology 2:99–106CrossRef

49.

Wolfe LS, Rostworowski K, Pappius HM (1976) The endogenous biosynthesis of prostaglandins by brain tissue in vitro. Can J Biochem 54(7):629–640CrossRefPubMed

50.

Gàti I, Bergström M, Westerberg G, Csòka K, Muhr C, Carlsson J (1990) Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma spheroids. Eur J Cancer 26(7):802–807CrossRefPubMed

51.

Van Solingen RM, Rosenstein ED, Mihailescu G, Drejka ML, Kalia A, Cohen AJ, Kramer N (2001) Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin. Am J Med 111(4):285–289CrossRefPubMed

52.

Allegretti M, Bertini R, Cesta MC, Bizzarri C, Di Bitondo R, Di Cioccio V, Galliera E, Berdini V, Topai A, Zampella G, Russo V, Di Bello N, Nano G, Nicolini L, Locati M, Fantucci P, Florio S, Colotta F (2005) 2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem 48(13):4312–4331CrossRefPubMed

53.

Chen M, Geng JG (2006) P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Arch Immunol Ther Exp (Warsz) 54:75–84CrossRef

54.

Sprague DL, Sowa JM, Elzey BD, Ratliff TL (2007) The role of platelet CD154 in the modulation in adaptive immunity. Immunol Res 39:185–193CrossRefPubMed

55.

Zanini D, Schmatz R, Pelinson LP, Pimentel VC, da Costa P, Cardoso AM, Martins CC, Schetinger CC, Baldissareli J, do Carmo Araújo M, Oliveira L, Chiesa J, Morsch VM, Leal DB, Schetinger MR (2013) Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer. Mol Cell Biochem 74(1–2):137–148CrossRef

56.

Urunsak IF, Gulec UK, Paydas S, Seyaoglu G, Guzel AB, Vardar MA (2012) Adenosine deaminase activity in patients with ovarian neoplasms. Arch Gynecol Obstet 286(1):155–159CrossRefPubMed

57.

Pirinççi N, Geçit I, Güneş M, Yüksel MB, Kaba M, Tanık S, Demir H, Aslan M (2012) Serum adenosine deaminase, catalase and carbonic anhydrase activities in patients with bladder cancer. Clinics 67(12):1443–1446PubMedCentralCrossRefPubMed

58.

Roberts EL, Roberts OT (2012) Plasma adenosine deaminase isoform 2 in cancer patients undergoing chemotherapy. Br J Biomed Sci 69(1):11–13PubMed

59.

Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P (2003) Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control 93(2):151–160CrossRef

60.

Zanotto-Filho A, Coradini K, Braganhol E, Schröder R, de Oliveira CM, Simões-Pires A, Battastini AM, Pohlmann AR, Guterres SS, Forcelini CM, Beck RC, Moreira JC (2013) Curcumin-loaded lipid-core nanocapsules as a strategy to improve pharmacological efficacy of curcumin in glioma treatment. Eur J Pharm Biopharm 83:156–167CrossRefPubMed

61.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Release 65(1–2):271–284MCrossRef

62.

Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J (2006) Biodistribuition of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats. J Drug Target 14:97–105CrossRefPubMed

Title: Ketoprofen-loaded polymeric nanocapsules selectively inhibit cancer cell growth in vitro and in preclinical model of glioblastoma multiforme
Authors: Elita F. da Silveira
Janaine M. Chassot
Fernanda C. Teixeira
Juliana H. Azambuja
Gabriela Debom
Fátima T. Beira
Francisco A. B. Del Pino
Adriana Lourenço
Ana P. Horn
Letícia Cruz
Roselia M. Spanevello
Elizandra Braganhol
Publication date: 01-12-2013
Publisher: Springer US
Published in: Investigational New Drugs / Issue 6/2013
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-013-0016-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 6/2013

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation

Chemo-sensitisation of HeLa cells to Etoposide by a Benzoxazine in the absence of DNA-PK inhibition

Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)

NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer